Valuation: Fortress Biotech, Inc.

Market Cap 84.38M 73.11M 69M 62.59M 117M 8.09B 118M 824M 318M 4.1B 317M 310M 13.04B P/E 2026 *
0.99x
P/E 2027 * -2.53x
Enterprise Value 84.38M 73.11M 69M 62.59M 117M 8.09B 118M 824M 318M 4.1B 317M 310M 13.04B EV / Sales 2026 *
1.07x
EV / Sales 2027 * 0.75x
Free-Float
77.3%
Yield 2026 *
-
Yield 2027 * -
1 day-0.05%
1 week-1.65%
Current month-1.55%
1 month-1.15%
3 months-10.96%
6 months+43.28%
Current year+94.31%
1 week 18.32
Extreme 18.32
18.76
1 month 18
Extreme 18
18.82
Current year 9.49
Extreme 9.49
21.43
1 year 6.27
Extreme 6.27
21.43
3 years 4.72
Extreme 4.72
21.43
5 years 4.72
Extreme 4.72
26.6
10 years 0
Extreme 0
26.69
Manager TitleAgeSince
Chief Executive Officer 71 19/12/2013
Director of Finance/CFO 51 21/02/2012
Director of Finance/CFO 36 15/08/2022
Director TitleAgeSince
Chairman 71 19/12/2013
Director/Board Member 60 19/12/2013
Director/Board Member 63 31/05/2006
Change 5-day change 1-year change 3-year change Capi.($)
-0.05%-1.65% - - 84.38M
+1.57%-4.11%+41.74%-4.64% 79.26B
+1.89%+0.78%+523.95%+30.03% 58.56B
+1.57%-0.31%-14.78%-34.90% 58.62B
+0.35%-3.14%-11.03%+26.34% 48.75B
+0.14%+1.88%+2.58%+150.36% 46.32B
+0.10%-1.57%+50.05%-15.20% 32.12B
+0.59%-3.60%+47.04%+92.49% 24.77B
-1.91%-5.19%-0.63%+142.35% 21.5B
-0.31%-2.23%+63.66%+99.29% 15.97B
Average +0.15%-1.72%+78.06%+54.01% 42.87B
Weighted average by Cap. +0.46%-1.65%+94.55%+36.39%

Financials

2026 *2027 *
Net sales 78.79M 68.28M 64.43M 58.45M 110M 7.55B 110M 769M 297M 3.83B 296M 289M 12.18B 113M 98.13M 92.61M 84.01M 158M 10.85B 159M 1.11B 426M 5.51B 425M 416M 17.51B
Net income 88.25M 76.47M 72.16M 65.47M 123M 8.46B 124M 862M 332M 4.29B 331M 324M 13.64B -37.81M -32.77M -30.92M -28.05M -52.62M -3.62B -53M -369M -142M -1.84B -142M -139M -5.85B
Net Debt - -
Logo Fortress Biotech, Inc.
Fortress Biotech, Inc. is a biopharmaceutical company focused on acquiring and advancing assets. The Company has eight marketed prescription pharmaceutical products and over 20 programs in development, with its majority-owned and majority-controlled partners and subsidiaries and partners and subsidiaries it founded and in which it holds significant minority ownership positions. Its portfolio is being commercialized and developed for various therapeutic areas, including oncology, dermatology, and rare diseases. Its dermatology products include Emrosi, Qbrexza, Amzeeq, Zilxi, Exelderm, Targadox, and Luxamend. Its late-stage product candidates include CUTX-101 (copper histidinate injection for Menkes disease), Triplex (cytomegalovirus (CMV) vaccine), and CAEL-101 (monoclonal antibody for AL amyloidosis). Its early and mid-stage product candidates include Dotinurad (urate transporter (URAT1) inhibitor for gout), MB-101 (IL13Rα2 CAR T Cell Program for Glioblastoma), and others.
Employees
78
Date Price Change Volume
14/09/26 US$18.44 -0.05% 1,310
11/09/26 US$18.45 -0.67% 3,632
10/09/26 US$18.58 -0.08% 8,855
09/09/26 US$18.59 -0.32% 10,123
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
2.530USD
Average target price
11.00USD
Spread / Average Target
+334.78%

Quarterly revenue - Rate of surprise

40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!